The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder.
The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder.
复制标题
DOI：
10.1016/j.brs.2016.03.010
复制
发表时间：
2016-05
影响因子：
7.7
通讯作者：
Wirecki TS
中科院分区：
文献类型：
--
作者：
Perera T;George MS;Grammer G;Janicak PG;Pascual-Leone A;Wirecki TS
前额经颅磁刺激（TMS）治疗每天重复4-6周（20-30次），是美国食品和药物管理局（FDA）批准用于治疗对既往抗抑郁药物无反应的成人重度抑郁症。2011年，领先的TMS临床提供商和研究人员创建了临床TMS协会（cTMS）（www.clinicaltmssociety.org，格林威治，CT，美国），于2013年成立。该共识审查由cTMS领导人撰写，由成员民意调查提供信息，并由管理委员会批准。它总结了在常规临床实践中使用TMS治疗抑郁症的安全性和有效性的现有证据。作者系统回顾了已发表的TMS抗抑郁治疗临床试验。然后使用牛津大学循证医学中心发布的证据等级框架对研究进行评估和分级。然后，作者总结了在常规临床实践环境中使用TMS治疗的要点，这些要点来自cTMS成员的讨论和民意调查。最后，每项临床建议摘要都附有支持该建议的经同行评审的已发表证据。当当前发表的临床试验证据不足或不完整时，在2014年和2015年年会上接受调查的cTMS成员中经验丰富的临床医生用户达成充分共识时，纳入专家意见。每日左前额经颅磁刺激有充分的证据表明，对治疗耐药或不耐受的抑郁症患者的急性期治疗是有效和安全的。遵循本文件中的临床建议，应能持续安全有效地使用这种令人兴奋的新治疗方式。
Prefrontal Transcranial Magnetic Stimulation (TMS) therapy repeated daily over 4–6 weeks (20–30 sessions) is US Food and Drug Administration (FDA) approved for treating Major Depressive Disorder in adults who have not responded to prior antidepressant medications. In 2011, leading TMS clinical providers and researchers created the Clinical TMS Society (cTMSs) (www.clinicaltmssociety.org, Greenwich, CT, USA), incorporated in 2013. This consensus review was written by cTMSs leaders, informed by membership polls, and approved by the governing board. It summarizes current evidence for the safety and efficacy of the use of TMS therapy for treating depression in routine clinical practice. Authors systematically reviewed the published TMS antidepressant therapy clinical trials. Studies were then assessed and graded on their strength of evidence using the Levels of Evidence framework published by the University of Oxford Centre for Evidence Based Medicine. The authors then summarize essentials for using TMS therapy in routine clinical practice settings derived from discussions and polls of cTMSs members. Finally, each summary clinical recommendation is presented with the substantiating peer-reviewed, published evidence supporting that recommendation. When the current published clinical trial evidence was insufficient or incomplete, expert opinion was included when sufficient consensus was available from experienced clinician users among the membership of the cTMSs, who were polled at the Annual Meetings in 2014 and 2015. Daily left prefrontal TMS has substantial evidence of efficacy and safety for treating the acute phase of depression in patients who are treatment resistant or intolerant. Following the clinical recommendations in this document should result in continued safe and effective use of this exciting new treatment modality.
登录
查看更多内容
影响因子：
5.7
作者：
Fox MD;Liu H;Pascual-Leone A
通讯作者：
Pascual-Leone A
影响因子：
7.7
作者：
Anderson, Berry S.;Kavanagh, Katie;Borckardt, Jeffrey J.;Nahas, Ziad H.;Kose, Samet;Lisanby, Sarah H.;McDonald, William M.;Avery, David;Sackeim, Harold A.;George, Mark S.
通讯作者：
George, Mark S.
DOI：
10.4088/jcp.11m07413
发表时间：
2012-04-01
期刊：
The Journal of clinical psychiatry
影响因子：
--
作者：
Connolly, K Ryan;Helmer, Amanda;O'Reardon, John P
通讯作者：
O'Reardon, John P
影响因子：
2.5
作者：
Deng Zhi-De;Lisanby, Sarah H.;Peterchev, Angel, V
通讯作者：
Peterchev, Angel, V
影响因子：
--
作者：
George, Mark S.;Lisanby, Sarah H.;Sackeim, Harold A.
通讯作者：
Sackeim, Harold A.